Small Cell Lung Cancer Market Analsyis
Small cell lung cancer can affect all the age groups; however, middle-aged and older adults are observed to be affected more as compared to other age groups. A gender gap can also be witnessed with a higher male Small Cell Lung Cancer incidence than females in the seven major markets.
As per DelveInsight, approximately 55% of the Small Cell Lung Cancer diagnosed pool consisted of males; however, during the last few years, the incidence gap has started to get narrower. The trend can be attributable to the rise in smoking, which is a significant risk factor of Small cell lung cancer
According to Delveinsight, around 25% of all the cases were of limited-stage whereas Extensive-stage SCLC constitutes the remaining 75% of the cases, in the 7MM (the US, EU5 (the UK, Germany, France, Italy and Spain), and Japan) in 2017.
The total Small-cell lung cancer incident cases are expected to increase with a CAGR of 1.7% for the study period 2017-30. Among the seven major markets, the US accounted for the highest Small Cell Lung Cancer incidence.
As per DelveInsight, the Small cell lung cancer market size is expected to grow at a CAGR of 15.2% during the study period (2017–30).
Rising prevalence, rich pipeline, healthcare spending, improved R&D, and discovery of novel targets, and approval of immune checkpoint inhibitors are some of the key factors expected to drive the Small Cell Lung Cancer Market in the upcoming years.
The key players in the Small Cell Lung Cancer Market includes:
Bristol-Myers Squibb
Merck
AstraZeneca
Genentech
G1 Therapeutics
PharmaMar
United Therapeutics
EpicentRx
Amgen
Fate Therapeutics
And many others.
For more information on Small Cell Lung Cancer Market, visit:
https://www.delveinsight.com/blog/small-cell-lung-cancer-market/